Digital Breast Tomosynthesis Equipment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Digital Breast Tomosynthesis Equipment Market is expected to register a CAGR of 13.5% during the forecast period. Digital breast tomosynthesis is a high-resolution limited-angle tomography technique that creates a 3-dimensional picture of the breast using X-rays. It is a new technology that helps in the early detection of breast cancer.

Digital breast tomosynthesis is especially useful in examining dense breasts and can improve and increase the ability to find breast cancer. It reduces the rate of false-positive readings (a reading that identifies normal tissue as an abnormality) and also reduces the need for a biopsy. It can be performed for any woman, but it is especially beneficial for women who have dense breasts.

According to the American Cancer Society in 2019, approximately 1 in 8 women (13%) will be diagnosed with invasive breast cancer in their lifetime and 1 in 39 women (3%) will die from breast cancer in the United States. Moreover, more than 150,000 breast cancer survivors are living with metastatic disease, three-fourths of whom were originally diagnosed with stage I-III in the United States. Increasing the prevalence of breast cancer worldwide, growing awareness about the use of tomosynthesis and technological advancements for developing new innovative imaging products are the key driving factors in digital breast tomosynthesis equipment market.

Key Market Trends

2D/3D Combination Mammography Systems Segment is Expected to Hold a Major Market Share in the Digital Breast Tomosynthesis (DBT) Equipment Market

2D/3D Combination Mammography Systems segment holds a significant market share in the digital breast tomosynthesis equipment market and is anticipated to show a similar trend over the forecast period. Combined 2D/3D mammography systems are superior to 2D mammography alone in the diagnosis of breast cancer because as shown by a number of large studies. As per the American Society of Clinical Oncology (ASCO) clinical trial report, a large US study of 4,54,850 patients found that combined 2D/3D Combination screening-detected 5.5 cancers per 1,000 women, compared with 4.3 cancers for 2D screening alone, a 28% higher detection rate with combined 2D/3D mammography systems. According to World Health Organization (WHO), breast cancer is the most frequent type of cancer among women globally, approximately 2.1 million women suffer from breast cancer every year, and with the highest number of cancer-related deaths among women. In the year 2018, it was estimated that approximately 627,000 women died from breast cancer that is nearly 15% of all cancer deaths among women globally. Furthermore, rising awareness about the use of these systems and high detection rates are the key driving factors in the 2D/3D combination mammography systems segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global digital breast tomosynthesis (DBT) equipment market due to the high demand for innovative products, increasing adoption of screening, and the presence of trained healthcare professionals in this region. According to the National Breast Cancer Foundation, in the year 2019, 62% of breast cancer cases were diagnosed at a localized stage. Female breast cancer represents approximately 15.2% of all new cancer cases in the United States. Furthermore, technological advancements in the field of breast imaging, the presence of well-established healthcare infrastructure and increasing healthcare spending are also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Digital Breast Tomosynthesis Equipment Market is Consolidated competitive and consists of a few major players. Some of the prominent players operating in the digital breast tomosynthesis (DBT) Equipment market are Hologic, Inc, GE Healthcare, Fujifilm Holdings Corporation, Siemens Healthineers, General Medical Merate SpA (IMS GIOTTO SPA), Planmed Oy, Analogic Corporation and Trivitron Healthcare.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support